GlassScriptPhysician profile
Adam Carrera
NPI 1477916682
$3,926.39
in general payments reported to CMS, 2019-2025
23 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $302 · 2021: $291 · 2022: $336 · 2023: $611 · 2024: $897 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987 · Gift: $10.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.85 |
| Gift | $10.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $826.47 | 2020-2025 | Clareon, Tryptyr, Ngenuity |
| Abbvie INC. | $686.74 | 2023-2025 | Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $454.42 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $235.79 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $226.78 | 2023-2025 | Tecnis Iol, Catalys System |
| Rxsight INC | $198.48 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $194.67 | 2021-2025 | Cequa |
| Allergan, INC. | $180.09 | 2020-2022 | |
| Harrow Eye, LLC | $134.10 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $125.97 | 2021-2025 | Acthar |
| New World Medical,INC. | $109.17 | 2021-2025 | Streamline, Via360, Kahook Dual Blade |
| Rayner Intraocular Lenses Limited | $91.43 | 2022-2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Regeneron Pharmaceuticals, INC. | $87.78 | 2023 | Eylea |
| Carl Zeiss Meditec USA, INC. | $83.43 | 2021-2023 | |
| Ocular Therapeutix, INC. | $79.74 | 2024-2025 | Dextenza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.51 | 2022-2023 | |
| Dompe US, INC. | $36.87 | 2024-2025 | Oxervate |
| Glaukos Corporation | $30.39 | 2024 | Idose |
| Biotissue Holdings INC. | $21.90 | 2024 | |
| Topcon Healthcare Solutions, INC. | $17.42 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.68 | 2020 | |
| Bausch & Lomb Americas INC. | $16.59 | 2024 | Xiidra, Miebo |
| Sight Sciences, INC. | $14.97 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Carrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.